Explore the words cloud of the Perfuze project. It provides you a very rough idea of what is the project "Perfuze" about.
The following table provides information about the project.
Coordinator |
PERFUZE LIMITED
Organization address contact info |
Coordinator Country | Ireland [IE] |
Total cost | 4˙473˙543 € |
EC max contribution | 2˙484˙012 € (56%) |
Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
Code Call | H2020-SMEInst-2018-2020-2 |
Funding Scheme | SME-2 |
Starting year | 2019 |
Duration (year-month-day) | from 2019-08-01 to 2021-07-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | PERFUZE LIMITED | IE (GALWAY) | coordinator | 2˙484˙012.00 |
Stroke is the third most common cause of death globally and is the leading cause of adult physical disability. Globally, seventeen million people had a stroke in 20152. Of these, 33% died and 33% were permanently disabled. A stroke occurs when a blood vessel in the brain is blocked by a clot, preventing blood flow, and causing brain damage. Stroke is a devastating disease.
Perfuze has developed aspiration catheter technology intended to ingest the clot in a single attempt. No accessory devices or sophisticated techniques are required, meaning the procedure can be performed by a single operator. This maximises the chance of complete clot ingestion within the occluded vessel, complete flow restoration and improved patient outcomes.
Multiple iterations have been required to reach the existing Millipede design. Pilot manufacturing lines utilising customised coiling and wire forming equipment have been built. Component and assembly drawings and specifications have been defined. Six preclinical animal studies have been performed to compliment proof-of-concept bench testing.
The potential market opportunity is huge. In the US and EU alone, it is valued at $2.5bn in 2018. The Perfuze platform is uniquely positioned to exploit the recent, dramatic clinical shift away from medical therapy to endovascular device treatment of ischemic stroke.
This SME Instrument Phase 2 will enable company scale up and creation of 52 jobs by 2024 and will generate over €17m in turnover.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PERFUZE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PERFUZE" are provided by the European Opendata Portal: CORDIS opendata.